All Stories

  1. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism

    Article • Drug Metabolism Reviews, June 2019, Taylor & Francis

    Gerd Mikus, Josefine Schulz, Robin Michelet

  2. Rivaroxaban and macitentan can be co-administered without dose adjustment but the combination of rivaroxaban and St. John´s Wort should be avoided

    Article • British Journal of Clinical Pharmacology, September 2018, Wiley

    Gerd Mikus

  3. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions

    Article • Basic & Clinical Pharmacology & Toxicology, August 2018, Wiley

    Gerd Mikus

  4. Isotopically labelled paroxetine standard allows for definite structure elucidation of the paroxetine tandem mass spectrum

    Article • Rapid Communications in Mass Spectrometry, June 2018, Wiley

    Gerd Mikus

  5. Higher chlorzoxazone clearance in obese children compared with nonobese peers

    Article • British Journal of Clinical Pharmacology, June 2018, Wiley

    Gerd Mikus

  6. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat

    Article • Journal of Pharmacy and Pharmacology, September 2017, Wiley

    Gerd Mikus

  7. In vitro inhibition of human UGT isoforms by ritonavir and cobicistat

    Article • Xenobiotica, September 2017, Taylor & Francis

    Gerd Mikus

  8. Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies

    Article • British Journal of Clinical Pharmacology, July 2017, Wiley

    Gerd Mikus

  9. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics

    Article • Clinical Pharmacology & Therapeutics, June 2017, Wiley

    Gerd Mikus

  10. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics

    Article • British Journal of Clinical Pharmacology, May 2017, Wiley

    Gerd Mikus

  11. Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz

    Article • The Journal of Clinical Pharmacology, February 2017, Wiley

    Gerd Mikus

  12. Appropriate use of opioids

    Article • European Journal of Pain, December 2016, Wiley

    Gerd Mikus, Professor Giustino Varrassi

  13. No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies

    Article • The Journal of Clinical Pharmacology, August 2016, Wiley

    Gerd Mikus

  14. CYP3A activity: towards dose adaptation to the individual

    Article • Expert Opinion on Drug Metabolism & Toxicology, March 2016, Informa Healthcare

    Gerd Mikus

  15. St. John’s wort treatment in women bears risks beyond pharmacokinetic drug interactions

    Article • Archives of Toxicology, May 2015, Springer Science + Business Media

    Gerd Mikus

  16. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole

    Article • The Journal of Clinical Pharmacology, February 2015, Wiley

    Gerd Mikus

  17. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans

    Article • British Journal of Clinical Pharmacology, January 2015, Wiley

    Gerd Mikus

  18. Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity

    Article • British Journal of Clinical Pharmacology, November 2014, Wiley

    Gerd Mikus

  19. Pre-systemic Elimination of Tilidine: Localization and Consequences for the Formation of the Active Metabolite Nortilidine

    Article • Basic & Clinical Pharmacology & Toxicology, October 2014, Wiley

    Gerd Mikus

  20. Deceptive argumentation against diagnostic microdosing of anticancer drugs

    Article • International Journal of Cancer, March 2014, Wiley

    Gerd Mikus

  21. Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation

    Article • Archives of Toxicology, December 2013, Springer Science + Business Media

    Gerd Mikus

  22. Concentration effect relationship of CYP3A inhibition by ritonavir in humans

    Article • European Journal of Clinical Pharmacology, June 2013, Springer Science + Business Media

    Gerd Mikus

  23. Pharmacological treatment of constipation in palliative care

    Article • Current Opinion in Supportive and Palliative Care, June 2013, Wolters Kluwer Health

    Gerd Mikus

  24. Daily Honey Consumption Does Not Change CYP3A Activity in Humans

    Article • The Journal of Clinical Pharmacology, August 2011, Wiley

    Gerd Mikus

  25. Pharmacogenomics of the triazole antifungal agent voriconazole

    Article • Pharmacogenomics, June 2011, Future Medicine

    Gerd Mikus

  26. Unerwünschte Wirkungen und Wechselwirkungen in der Analgetikatherapie

    Article • Therapeutische Umschau, January 2011, Hogrefe Publishing Group

    Gerd Mikus

  27. Unerwünschte Arzneimittelwirkungen (UAW) und Arzneimittel-Interaktionen – Definition und Einteilung

    Article • Therapeutische Umschau, January 2011, Hogrefe Publishing Group

    Gerd Mikus

  28. Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole

    Article • British Journal of Clinical Pharmacology, July 2009, Wiley

    Gerd Mikus

  29. Telemetrie

    Article • Herzschrittmachertherapie + Elektrophysiologie, September 2008, Springer Science + Business Media

    Gerd Mikus

  30. Misleading results of screening for illicit drugs during efavirenz treatment

    Article • AIDS, June 2007, Wolters Kluwer Health

    Gerd Mikus

  31. Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response

    Article • Current Pharmacogenomics, March 2005, Bentham Science Publishers

    Gerd Mikus

  32. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine

    Article • Addiction Biology, December 2003, Taylor & Francis

    Gerd Mikus

  33. Pharmacology (82)

    Article • Pain Practice, January 2001, Wiley

    Gerd Mikus

  34. Gabapentin Enhances the Analgesic Effect of Morphine in Healthy Volunteers

    Article • Anesthesia & Analgesia, July 2000, Wolters Kluwer Health

    Gerd Mikus

  35. Gabapentin Enhances the Analgesic Effect of Morphine in Healthy Volunteers

    Article • Anesthesia & Analgesia, July 2000, Wolters Kluwer Health

    Gerd Mikus

  36. Omeprazole associated leuco-and thrombocytaemia

    Article • Gastroenterology, April 2000, Elsevier

    Gerd Mikus

  37. Morphine-related metabolites differentially activate adenylyl cyclase isozymes after acute and chronic administration

    Article • FEBS Letters, March 2000, Wiley

    Gerd Mikus

  38. Relevance of deficient CYP2D6 in opiate dependence

    Article • Pharmacogenetics, December 1998, Wolters Kluwer Health

    Gerd Mikus

  39. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

    Article • Pain, May 1998, Wolters Kluwer Health

    Gerd Mikus

  40. Loss of analgesic effect of morphine due to coadministration of rifampin

    Article • Pain, August 1997, Wolters Kluwer Health

    Gerd Mikus

  41. Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans*

    Article • Clinical Pharmacology & Therapeutics, October 1995, Nature

    Gerd Mikus

  42. Primary and secondary oxidative metabolism of dextromethorphan

    Article • Biochemical Pharmacology, February 1993, Elsevier

    Gerd Mikus

  43. Enantioselective gallopamil protein binding

    Article • Chirality, January 1993, Wiley

    Gerd Mikus

  44. Codeine o-demethylation: Rat strain differences and the effects of inhibitors

    Article • Biochemical Pharmacology, March 1991, Elsevier

    Gerd Mikus